Gelatin hydrogel carrier with the w9-peptide elicits synergistic effects on bmp-2-induced bone regeneration

Journal of Oral Biosciences

Volumn 55, Issue 4, 2013, Pages 217-223

  Mamuna, Abdullah Al ^a   Khana, Abdulla Al Masud ^a   Allesb, Neil ^b   Matsuic, Makoto ^c   Tabata, Yasuhiko ^c   Ohya, Keiichi ^a   Aokia, Kazuhiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF PERADENIYA   (Sri Lanka)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Anabolic peptide; Bone morphogenetic protein (BMP) 2; Controlled release; Gelatin hydrogel; Type 1 collagen

Indexed keywords

EID: 84892600158     PISSN: 13490079     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.job.2013.06.008     Document Type: Article

References (41)

1. Wang EA, Rosen V, Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990;87:2220-4.
2. Smith JL, Jin L, Parsons T, Turek T, Ron E, Philbrook CM, Kenley RA, Marden L, Hollinger J, Bostrom MPG, Tomin E, Lane JM. Osseous regeneration in preclinical models using bioabsorbable delivery technology for recombinant human bone morphogenetic protein-2 (Rhbmp-2). J Control Release 1995;36:183-95.
3. Bostrom M, Lane JM, Tomin E, Browne M, Berberian W, Turek T, Smith J, Wozney J, Schildhaner T. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop Relat Res 1996;327:272-82.
4. Takaoka K, Nakahara H, Yoshikawa H, Masuhara K, Tsuda T, Ono K. Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein. Clin Orthop Relat Res 1988;234:250-4.
5. Urist MR, Lietze A, Dawson E. p-tricalcium phosphate delivery system for bone morphogenetic protein. Clin Orthop Relat Res 1984;187:277-80.
6. Gao TJ, Lindholm TS, Marttinen A, Puolakka T. Bone inductive potential and dose-dependent response of bovine bone morphogenetic protein combined with type IV collagen carrier. Ann Chir Gynaecol Suppl 1993;207:77-84.
7. Takaoka K, Koezuka M, Nakahara H. Telopeptide-depleted bovine skin collagen as a carrier for bone morphogenetic protein. J Orthop Res 1991;9:902-7.
8. Sigurdsson TJ, Nygaard L, Tatakis DN, Fu E, Turek TJ, Jin L, Wozney JM, Wikesjo UM. Periodontal repair in dogs: evaluation of rhBMP-2 carriers. Int J Period- ontics Restorative Dent 1996;16:524-37.
9. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages-Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000;25:376-81.
10. Biase PD, Capanna R. Clinical applications of BMPs. Injury 2005;36:43-6.
11. Uludag H, Gao T, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am 2001;83:128-35.
12. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001;19:255-65.
13. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 2003;55:1613-29.
14. Tabata Y, Hijikata S, Ikada Y. Enhanced vascularization and tissue granulation by basic fibroblast growth-factor impregnated in gelatin hydrogels. J Control Release 1994;31:189-99.
15. Ikada Y, Tabata Y. Protein release from gelatin matrices. Adv Drug Deliv Rev 1998;31:287-301.
16. Tabata Y, Nagano A, Muniruzzaman M, Ikada Y. In vitro sorption and desorption of basic fibroblast growth factor from biodegradable hydrogels. Biomaterials 1998(19):1781-9.
17. Yamamoto M, Ikada Y, Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J Biomater Sci Polym Ed 2001;12:77-88.
18. Yamamoto M, Takahashi Y, Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 2003;24:4375-83.
19. Yamamoto M, Tabata Y, Hong L, Miyamoto S, Hashimoto N, Ikada Y. Bone regeneration by transforming growth factor p 1 released from a biodegradable hydrogel. J Control Release 2000;64:133-42.
20. Ozeki M, Ishii T, Hirano Y, Tabata Y. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. J Drug Target 2001;9:461-71.
21. Yamamoto M, Tabata Y, Ikada Y. Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed, 9; 439-58.
22. Hong L, Tabata Y, Yamamoto M, Miyamoto S, Yamada K, Hashimoto N, Ikada Y. Comparison of bone regeneration in a rabbit skull defect by recombinant human BMP-2 incorporated in biodegradable hydrogel and in solution J Biomater Sci Polym Ed 1998;9:1001-14.
23. Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y. Skull bone regeneration in nonhuman primates by controlled release of bone morpho-genetic protein-2 from a biodegradable hydrogel. Tissue Eng 2007;3:293-300.
24. Yamamoto M, Takahashi Y, Tabata Y. Bone induction by controlled release of BMP-2 from a biodegradable hydrogel in various animal species?from mouse to non-human primate. Adv Biomaterials 2005;288-289:253-6.
25. Yamamoto M, Takahashi Y, Tabata Y. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 2006;12:1305-11.
26. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF a binding to its receptor. Nat Biotechnol 1997;15:1266-70.
27. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M, Yamaguchi A, Deprez P, Mollat P, Murali R, Ohya K, Horne WC, Baron RA. TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 2006;116:1525-34.
28. Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, Ohya K, Aoki K. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum 2007;56: 1164-74.
29. Khan M, Alles N, Soysa NS, Mamun MA, Nagano K, Mikami R, Furuya Y, Yasuda H, Ohya K, Aoki K. The local administration of TNF-a and RANKL antagonist peptide promotes BMP-2-induced bone formation. J Oral Biosci 2013;55: 47-54.
30. Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida K, Yasuda H. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitoryactivity. J Biol Chem 2013;288:5562-71.
31. Nagano K, Alles N, Mian AH, Shimoda A, Morimoto N, Tamura Y, Shimokawa H, Akiyoshi K, Ohya K, Aoki K. The tumor necrosis factor type 2 receptor plays a protective role in tumor necrosis factor-a-induced bone resorption lacunae on mouse calvariae. J Bone Miner Metab 2011;29:671-81.
32. Hirata K, Tsukazaki T, Kadowaki A, Furukawa K, Shibata Y, Moriishi T, Okubo Y, Bessho K, Komori T, Mizuno A, Yamaguchi A. Transplantation of skin fibroblasts expressing BMP-2 promotes bone repair more effectively than those expressing Runx2. Bone 2003;32:502-12.
33. Alles N, Soysa NS, Hayashi J, Khan M, Shimoda A, Shimokawa H, Ritzeler O, Akiyoshi K, Aoki K, Ohya K. Suppression of NF-kB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology 2010;151: 4626-34.
34. Suzuki Y, Aoki K, Saito H, Umeda M, Nitta H, Baron R, Ohya K. A tumor necrosis factor-a antagonist inhibits inflammatory bone resorption induced by Porphyromonas gingivalis infection in mice. J Periodontal Res 2006;41:81-91.
35. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
36. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. JBone Miner Res 2013;28:2-17.
37. Nagahama K, Aoki K, Nonaka K, Saito H, Takahashi M, Varghese BJ, Shimokawa H, Azuma M, Ohya K, Ohyama K. The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone 2004;35:1059-68.
38. Sandy C, Marks Jr, Hermey DC. The structure and development of bone. In: Bilezikian JP, Raisz LA, Rodan GA, editors. Principles of bone biology. Academic Press; 1996. p. 103-13.
39. Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 2008;23: 2007-17.
40. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteo-blast cultures. J Bone Miner Res 2003;18:1186-97.
41. Itoh K, Udagawa N,KatagiriT,IemuraS,UenoN,Yasuda H, Higashio K, QuinnJM, Gillespie MT, Martin TJ, Suda T, Takahashi N. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kB ligand. Endocrinology 2001;142:3656-62.